The United States Patent and Trademark Office (USPTO) has granted patent US12582684B2, titled 'Compositions and methods for the treatment of wounds, disorders, and diseases of the skin,' to Krystal Biotech, Inc. The patent, filed on June 27, 2023, and granted on March 24, 2026, covers pharmaceutical compositions comprising polynucleotides aimed at enhancing levels of Collagen alpha-1 (VII) chain, Lysyl hydroxylase 3, and Keratin type I cytoskeletal 17 polypeptides. These compositions are intended for the prophylactic, palliative, or therapeutic relief of skin wounds, disorders, and diseases, with a specific mention of epidermolysis bullosa.

This patent grant signifies the formal recognition of novel intellectual property in the biotechnology and pharmaceutical sector. While not imposing direct compliance obligations on other entities, it establishes exclusive rights for Krystal Biotech, Inc. regarding the patented technology. Companies operating in the dermatological treatment space, particularly those developing gene therapies or wound care solutions, should be aware of this patent to avoid potential infringement and to understand the competitive landscape. No specific compliance deadlines or penalties are associated with this patent grant itself, but infringement could lead to legal action.